FGFR4 and hepatocellular carcinoma: The development of new drugs for HCC treatment may not be as impressive as for some other tumors, and few predictive biomarkers have yet been identified (except AFP for ramucirumab and perhaps FGF19 for FGFR4 inhibitors).